Thymopentin, G-CSF and chemotherapy-associated fever
Randomized study in people · 1994
- What was studied
- 100 patients receiving highly myelosuppressive chemotherapy for advanced carcinoma randomized across four arms.
- Main finding
- Chemotherapy-related febrile episodes · 52% with thymopentin versus 64% with placebo. The difference was not statistically significant.
Reported findings and study design
Reported findings
Prospective randomized comparison of thymopentin, subcutaneous G-CSF, both agents, and placebo. Cochrane’s extraction lists thymopentin 50 mg IM every other day starting two days after chemotherapy and continuing until the next cycle.
Population or model 100 patients receiving highly myelosuppressive chemotherapy for advanced carcinoma randomized across four arms.
Dose, route and schedule
Prospective randomized comparison of thymopentin, subcutaneous G-CSF, both agents, and placebo. Cochrane’s extraction lists thymopentin 50 mg IM every other day starting two days after chemotherapy and continuing until the next cycle.
Protocol source ↗ · Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Chemotherapy-related febrile episodes | 52% with thymopentin versus 64% with placebo. The difference was not statistically significant. | |
| G-CSF and combination | 22% with G-CSF versus 64% with placebo (p<0.001). Adding thymopentin did not significantly improve the result with G-CSF alone. |
The accessible journal abstract does not supply per-arm denominators or a combination-arm percentage. The study measured supportive-care outcomes during chemotherapy.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The accessible journal abstract does not supply per-arm denominators or a combination-arm percentage. The study measured supportive-care outcomes during chemotherapy.
Source details
Original indexed abstract
Original indexed abstract for findings. The dosing detail comes from the Cochrane study description.
Sources checked
Added to the library
Citation
V. Gebbia, R. Valenza, A. Testa, G. Cannata, N. Borsellino, N. Gebbia. Thymopentin, G-CSF and chemotherapy-associated fever Anticancer Research 14(2B), 731–734.